Furostilbestrol: Difference between revisions

Latest revision as of 11:01, 15 February 2025

Furostilbestrol[edit]

Chemical structure of Furostilbestrol

Furostilbestrol is a synthetic, nonsteroidal estrogen of the stilbestrol group. It is structurally related to diethylstilbestrol (DES) and was developed for use in hormone replacement therapy and other estrogen-related treatments. However, due to concerns about the safety and side effects of stilbestrol compounds, its use has been limited.

Chemical Structure and Properties[edit]

Furostilbestrol is characterized by its stilbene backbone, which is a common feature among synthetic estrogens of this class. The presence of a furan ring distinguishes it from other stilbestrol derivatives. This structural modification was intended to alter its pharmacokinetic properties and reduce potential side effects.

Mechanism of Action[edit]

As an estrogen, furostilbestrol binds to and activates the estrogen receptors in various tissues. This activation leads to the transcription of estrogen-responsive genes, which mediate the physiological effects of estrogens, such as the regulation of the menstrual cycle, maintenance of bone density, and modulation of lipid metabolism.

Clinical Uses[edit]

Furostilbestrol was primarily investigated for its potential in hormone replacement therapy for postmenopausal women and in the treatment of certain hormone-sensitive cancers, such as breast cancer and prostate cancer. However, its clinical use has been overshadowed by concerns regarding the carcinogenic potential of stilbestrol compounds.

Safety and Side Effects[edit]

The use of furostilbestrol, like other stilbestrols, has been associated with an increased risk of endometrial cancer, breast cancer, and other estrogen-related adverse effects. These risks have led to a decline in its use in favor of other estrogenic compounds with better safety profiles.

Related Compounds[edit]

Related Pages[edit]

@@ Line 1: / Line 1: @@
-'''Diethylstilbestrol''' (DES), also known as '''stilboestrol''' or '''furostilbestrol''', is a synthetic nonsteroidal estrogen that was first synthesized in 1938. It was prescribed from the 1940s through the early 1970s to prevent miscarriage, premature labor, and related complications of pregnancy. The use of DES declined after studies in the early 1970s showed that it was associated with an increased risk of clear cell adenocarcinoma (CCA) in the daughters of women who had taken DES during pregnancy, a condition known as DES syndrome.
+{{DISPLAYTITLE:Furostilbestrol}}
-==Medical Uses==
+== Furostilbestrol ==
-Originally, DES was used to support pregnancy in women with a history of recurrent miscarriage, preterm labor, and other pregnancy-related complications. It was believed to act as a form of hormone replacement therapy by supplementing estrogen levels, which are crucial for maintaining pregnancy.
-==Adverse Effects==
+[[File:Furostilbestrol.svg|thumb|right|Chemical structure of Furostilbestrol]]
-The adverse effects of DES exposure are significant and have led to changes in medical practice. DES daughters, or females exposed to DES in utero, have an increased risk of developing clear cell adenocarcinoma of the vagina and cervix, as well as fertility problems and pregnancy complications. DES sons, or males exposed to DES in utero, may experience genital abnormalities and fertility issues, although the risks are less well defined than for DES daughters.
-==Mechanism of Action==
+'''Furostilbestrol''' is a synthetic, nonsteroidal estrogen of the stilbestrol group. It is structurally related to [[diethylstilbestrol]] (DES) and was developed for use in [[hormone replacement therapy]] and other estrogen-related treatments. However, due to concerns about the safety and side effects of stilbestrol compounds, its use has been limited.
-DES functions as an estrogen agonist. It binds to estrogen receptors in the body, mimicking the effects of natural estrogen. This action was intended to support the endometrium and maintain pregnancy, but it also led to unintended adverse effects due to its potency and the duration of exposure.
-==History==
+== Chemical Structure and Properties ==
-The history of DES use is a cautionary tale in medical science. Initially hailed as a miracle drug for preventing miscarriages, its widespread use was eventually curtailed due to the discovery of its link to cancer and other serious health issues in the children of women who took the drug during pregnancy.
-==Regulation and Legacy==
+Furostilbestrol is characterized by its stilbene backbone, which is a common feature among synthetic estrogens of this class. The presence of a furan ring distinguishes it from other stilbestrol derivatives. This structural modification was intended to alter its pharmacokinetic properties and reduce potential side effects.
-The regulatory response to the discovery of DES's adverse effects was significant. In many countries, the use of DES during pregnancy was banned or severely restricted. The DES tragedy has had a lasting impact on drug regulation and monitoring, leading to more stringent testing requirements for drugs and greater awareness of the potential for long-term effects of pharmaceuticals.
-==See Also==
+== Mechanism of Action ==
-* [[Estrogen]]
+As an estrogen, furostilbestrol binds to and activates the [[estrogen receptor]]s in various tissues. This activation leads to the transcription of estrogen-responsive genes, which mediate the physiological effects of estrogens, such as the regulation of the [[menstrual cycle]], maintenance of [[bone density]], and modulation of [[lipid metabolism]].
+== Clinical Uses ==
+Furostilbestrol was primarily investigated for its potential in [[hormone replacement therapy]] for postmenopausal women and in the treatment of certain [[hormone-sensitive cancers]], such as [[breast cancer]] and [[prostate cancer]]. However, its clinical use has been overshadowed by concerns regarding the carcinogenic potential of stilbestrol compounds.
+== Safety and Side Effects ==
+The use of furostilbestrol, like other stilbestrols, has been associated with an increased risk of [[endometrial cancer]], [[breast cancer]], and other estrogen-related adverse effects. These risks have led to a decline in its use in favor of other estrogenic compounds with better safety profiles.
+== Related Compounds ==
+* [[Diethylstilbestrol]]
+* [[Hexestrol]]
+* [[Benzestrol]]
+== Related Pages ==
+* [[Estrogen receptor]]
 * [[Hormone replacement therapy]]
-* [[Clear cell adenocarcinoma]]
+* [[Breast cancer]]
-* [[Pregnancy complications]]
+* [[Prostate cancer]]
-==References==
-<references/>
-[[Category:Endocrine disruptors]]
+[[Category:Estrogens]]
-[[Category:Synthetic estrogens]]
+[[Category:Stilbestrols]]
-[[Category:Drug safety]]
+[[Category:Synthetic hormones]]
-{{medicine-stub}}